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PL1: MOUSE MODELS OF THORACIC CANCERS. 
WHAT DO THEY TEACH US?
ANTON BERNS
Oncode Institute; Division of Molecular Genetics, The Netherlands Cancer Institute, Amsterdam, Netherlands 
(e-mail: a.berns@nki.nl)
Lung cancers belong to the most lethal human malignancies. In particular, patients with small cell 
lung cancer (SCLC) and lung squamous cell carcinoma (LSCC) show very poor survival statistics due to 
the often late detection, early metastatic spread and chemo-resistance of the tumors. We have generated 
multiple mouse models for the various lung cancer subtypes and studied how closely they resemble their 
human counterparts, how these tumors develop over time, from which cell type they originate, what addi-
tional recurrent genomic alterations are recurrently found, and how the combination of the cell-of-origin 
and the driver lesions infl uence the response to single drugs or drug combinations. We observed that the 
mouse tumors showed remarkable resemblance to their cognate human counterparts. This includes their 
marker profi les, their specifi c location within the tissue, their immunophenotypes and their refractoriness 
to the standard treatments. Remarkably, we also observed substantial intra-tumor heterogeneity and 
tumor cell plasticity, this in spite of the fact that the mouse tumors are driven by a set of well-defi ned 
driver lesions and do not exhibit a high mutation load as is the case for most human lung cancers. Interest-
ingly, it appears that also the cell-of-origin of these mouse tumors can be quite diverse resulting in tumors 
that signifi cantly diff er although carrying the same driver mutations. The lessons learned from studying 
these models and how this might help designing more eff ective treatments for patients with lung cancer 
will be discussed.
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PL2: UBIQUITIN AND AUTOPHAGY NETWORKS IN CANCER 
PATHOGENESIS
IVAN DIKIC
Institute of Biochemistry II, Frankfurt Cancer Institute and Buchmann Institute for Molecular Life Sciences, 
Goethe University, Frankfurt/Main, Germany 
(e-mail: ivan.dikic@biochem2.de)
Autophagy and Ubiquitin proteasome degradation systems are major quality control pathways for 
the maintenance of cellular homeostasis. As such they provide protection against rapid aging and various 
human diseases. An increasing number of distinct functions have been assigned to diff erent types of ubiq-
uitin modifi cations (mono ubiquitin, Lysine-linked and Met1-linked ubiquitin chains). We have cloned a 
number of Ub receptors that are able to mediate a variety of Ub functions including TLS polymerases in 
DNA repair, proteasomal degradation, receptor endocytosis and innate immunity. Deregulation of these 
pathways has been link to the development of variety of human cancers. We have recently identifi ed 
SPRTN, a novel Ub-binding protein, whose germline mutations causes Ruijs-Aalfs syndrome (RJALS). 
This syndrome is characterized by early onset hepatocellular carcinoma, genome instability and progeria. 
Cells derived from patients with Ruijs-Aalfs syndrome are impaired in the resolution of covalent DPCs 
and exhibit leakage of the G2/M cell cycle checkpoint and proliferation defects. In mice, the complete 
knockout of Sprtn is embryonically lethal, whereas Sprtn hypomorphic mice are viable despite reduced 
Spartan expression. Characterization of the Sprtny118c/y118c mouse that contains the mutation that causes 
early hepatocarcinoma in humans will be presented. Moreover, our current translational activities in the 
newly established Frankfurt Cancer Institute will be discussed.
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K: THE ROLE OF ENDOCRINE FGFs IN METABOLISM AND CANCER
JOSEPH SCHLESSINGER
Yale University School of Medicine, New Haven CT, USA 
(e-mail: joseph.schlessinger@yale.edu)
Tyrosine phosphorylation of cellular proteins plays an important role in the control of cell prolifera-
tion, diff erentiation, cell metabolism as well as other important cellular processes. Ligand binding to the 
extracellular ligand binding domain of receptor tyrosine kinases induces receptor dimerization, a step 
crucial for activation of the catalytic domain and for tyrosine autophosphorylation; both processes are 
mediated by an intermolecular process. A large family of growth factors such as platelet derived growth 
factor (PDGF), stem cell factor (SCF), colony stimulating factor (CSF), and nerve growth factor (NGF), 
among many others are dimeric proteins. These growth factors induce receptor dimerization by virtue of 
their dimeric nature. Canonical fi broblast growth factors bind to their receptor monovalently, and when 
added alone are unable to induce dimerization and activation of FGF-receptors. Canonical FGF-induced 
dimerization of FGF-receptors is mediated by heparin sulfate proteoglycans. Endocrine FGFs, FGF19, 
FGF21 and FGF23 are circulating hormones that regulate metabolic processes in a variety of tissues. They 
signal through FGFRs in a manner that requires a Klotho protein. It was proposed that Klotho proteins, 
which are cell surface proteins with tandem glycoside hydrolase domains, act as co-receptors for FGFR 
activation by endocrine FGFs, playing roles analogous to heparan sulfate proteoglycans in canonical FGF 
signaling. By determining crystal structures of free and ligand-bound β-Klotho extracellular regions, we 
show that β-Klotho in fact serves as a primary high-affi  nity cell-surface receptor for FGF21, with FGFR1c 
functioning as a catalytic subunit that mediates intracellular signaling.
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L1: CANCER STEM CELLS: NEW DRIVERS AND MECHANISMS
UGO CAVALLARO
Unit of Gynecological Oncology Research, European Institute of Oncology, Milano, Italy 
(e-mail: ugo.cavallaro@ieo.it)
The cancer stem cell (CSC) theory has revolutionized the tumor biology fi eld, in that it pointed to a 
subpopulation of malignant cells that accounts for the onset, progression, heterogeneity, metastatic spread 
and resistance to treatments. Such a theory would explain very well the biological features and the clinical 
evolution of ovarian cancer (OC), including its peritoneal dissemination, the high rate of relapse in spite of 
optimal tumor debulking, and the unresponsiveness to chemotherapy, namely the factors that determine 
the high mortality rate of this neoplasm. Nevertheless, while experimental evidence has supported the 
existence and the pathogenic function of ovarian CSC (OCSC), this subset of cells has remained elusive, 
and the contribution of OCSC to specifi c aspects of OC biology remains to be elucidated.
In an att empt to identify and characterize OCSC, we have opted to rely on the intrinsic biological 
properties of this cell subpopulation rather than on the expression of markers inferred from either CSC of 
diff erent solid tumor types or OC cell lines (that often fail to recapitulate the disease). We established a 
number of primary cell cultures from patient-derived tissue, utilizing not only OC samples but also their 
normal counterparts, i.e. ovarian surface epithelium and fallopian tube epithelium for the fi mbriae. Cul-
turing these cells under conditions that are selectively permissive for the stem cell compartment, we could 
obtain the molecular portrait of OCSC vs. normal SC.
Our approach has revealed a series of OCSC-specifi c biomarkers which may off er new strategies for 
the prospective purifi cation and characterization of this cell subpopulation. In addition, we have identifi ed 
novel players that not only play a causal role in OC stemness, but also represent potential targets for 
molecular therapies.
Thus, we present an approach that, by capitalizing on clinically relevant model systems and on the 
unbiased, function-based defi nition of OCSC, provided novel insights into the nature and function of this 
elusive cell subset. These results might set the stage for innovative treatments aimed at the eradication of 
ovarian cancer through the inactivation of its CSC compartment.
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L2: DNA-PROTEIN CROSSLINK PROTEOLYSIS REPAIR IN PREMATURE 
AGEING AND CANCER
KRISTIJAN RAMADAN
Cancer Research UK and Medical Research Council Oxford Institute for Radiation Oncology, 
Department of Oncology, University of Oxford, Oxford, United Kingdom 
(e-mail: kristijan.ramadan@oncology.ox.ac.uk)
DNA-protein crosslinks (DPCs) are a specifi c type of DNA lesion consisting of a protein covalently 
and irreversibly bound to DNA, which arise after exposure to physical and chemical crosslinking agents. 
DPCs are bulky and pose a barrier to DNA replication and transcription. Persistence of DPCs during 
S-phase causes DNA replication stress and genome instability. Recent work from several laboratories dis-
covered a specialized repair pathway for DPCs, namely DPC proteolysis (DPCP) repair. DPCP repair is 
carried out by replication-coupled DNA-dependent metalloproteases: Wss1 in yeast and SPRTN (Spartan) 
in metazoans. Mutations in the DPC protease SPRTN cause premature aging and liver cancer in humans 
and mice; thus, effi  cient DPC repair has great medical value. Here, I will discuss our recent progress on the 
regulation of DPCP repair and discuss the relevance of DPCP repair for cancer therapy.
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L3: GENOTYPE-IMMUNOPHENOTYPE CORRELATION IN CANCER
HUBERT HACKL
Division of Bioinformatics, Biocenter, Medical University of Innsbruck, Innsbruck, Austria 
(e-mail: hubert.hackl@i-med.ac.at)
Recent breakthroughs in cancer immune therapy has sparked intense research on tumor- immune 
system interactions and - at least a part of - patients benefi t and show long-term response. Patients with 
genomic changes in the tumor such as microsatellite instability, hypermutation, and encoded factors 
involved in MHC processing have been shown to profi t from checkpoint blocker immune therapy. One of 
the mechanisms might involve defi cient DNA repair genes raising the chance of release of immunogenic 
neo-antigens. Resistance to immunotherapy is due to a complex tumor microenvironment that counteracts 
antitumor immunity through a combination of poorly antigenic tumor cells and an immunosuppressive 
tumor microenvironment. Using available RNA sequencing and whole exome sequencing data from The 
Cancer Genome Atlas (TCGA) as well as computational genomics tools we systematically analyzed 20 dif-
ferent solid cancer types from > 8000 patients predicted neo-antigens, estimated tumor-infi ltrating lym-
phocytes (TILs), cytolytic activity, and identifi ed determinants of tumor immunogenicity. In particular we 
are following up on how tumor-intrinsic factors and oncogenic pathways (involving e.g. MYC) shaping 
the immune landscape and impact the evasion of antitumor responses or which molecules are involved in 
the regulation of the expression of PD-L1 and other check points. I will present data addressing the cor-
relation of patients sharing specifi c tumor genotypes or molecular subtypes with increased expression of 
MHC related genes, immune modulators, and activating or suppressive cells from the innate/adaptive 
immune system as evident in BRAF versus RAS genotypes in thyroid carcinoma. Another focus will be on 
how defi cient genes encoding factors of mismatch repair (MLH1) in colorectal cancer or recombinational 
repair (BRAC1/2) in ovarian cancer are associated with the immune system and fi nally will discuss how 
the immune system surveil the tumor and intra tumor heterogeneity (immunoediting).
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L4: THE MUTATION LANDSCAPE OF CANCERS SERVE 
AS RECORDS OF EARLY MALIGNANT TRANSFORMATION
ROSA KARLIĆ1, KIRSTEN KUBLER2,3,4, WILLIAM D FOULKES5,6, PAZ POLAK7, GAD GETZ2,3,4
1 Bioinformatics Group, Division of Molecular Biology, Department of Biology, Faculty of Science, 
University of Zagreb, Zagreb, Croatia 
(e-mail: rosa@bioinfo.hr) 
2 The Broad Institute of MIT and Harvard, Cambridge, Massachusett s, USA 
3 Center for Cancer Research, Massachusett s General Hospital, Charlestown, Massachusett s, USA. 
4 Harvard Medical School, Boston, Massachusett s, USA. 
5 Department of Human Genetics, McGill University, Montreal, QC, Canada, 
6 Lady Davis Institute for Medical Research and Research Institute McGill University Health Centre, 
McGill University, Montreal, Quebec, Canada. 
7 Icahn School of Medicine at Mount Sinai, New York, NY, USA
A fundamental question in cancer biology is how the cell lineage infl uences the cell’s susceptibility to 
malignant transformation. Cell properties are encoded in the cell type-specifi c chromatin structure and we 
previously demonstrated that the landscape of somatic mutations in cancer is associated with the chroma-
tin marks of the cell-of-origin (Polak et al, Nature, 2015). Many of these mutations accumulate before 
malignant transformation and serve as a historical record of the original normal cell.
Here, we show that this principle is generalizable to common cancer types and provides new insights 
into the molecular events of cancer initiation. We extended our analysis to include 2,641 whole genomes 
across 30 cancer types and epigenetic modifi cations from 98 normal tissue types. We found that 28/30 can-
cer types originated from a biologically plausible cell-of-origin. In 25 cancer types, the tumor originated 
from a cell type that was its direct normal cell counterpart (or a related cell type). In three cancer types 
(esophageal, pancreatic ductal and biliary adenocarcinomas) the best-matched normal cell type indicated 
metaplasia. In the remaining two cancer types, we did not fi nd a good match among the normal cell types, 
due to the lack of relevant epigenetic data.
We analyzed in more detail diff erent breast cancer subtypes. We found that basal-like tumors appear 
to originate from luminal progenitor cells, while all other subtypes (luminal A, luminal B, and HER2-
enriched) arise from mature luminal cells. Furthermore, this association held true when accounting for 
various gene inactivation events. Irrespective of the exact mechanism of inactivation, all BRCA1/2- and 
RAD51C-altered basal-like tumors best matched to luminal progenitors while BRCA1/2- and CHEK2 
-mutated luminal A/B subtypes best matched mature luminal cells, implying that the inactivation of spe-
cifi c genes was less crucial than the cell-of-origin for driving the formation of subtypes. Taken together, 
our fi ndings highlight the crucial role of the specifi c cell type of origin in shaping the mutational landscape 
and early tumor evolution.
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L5: MICROENVIRONMENTAL REGULATION OF METASTASIS
JONATHAN SLEEMAN
M icrovascular Biology and Pathobiology, European Center for Angioscience, Medical Faculty Mannheim 
of the University of Heidelberg, Heidelberg, Germany 
(e-mail: sleeman@medma.uni-heidelberg.de)
The reception and integration of the plethora of signals a cell receives from its microenvironment is 
decisive in determining cell behaviour. External signals that regulate cell behaviour and properties include 
signalling molecules such as growth factors and cytokines, extra cellular matrix (ECM) components, con-
tacts with other cells, mechanical stress, matrix stiff ness and roughness, the redox status of the surround-
ing milieu, and the local oxygen tension. Perturbation of extracellular cues or an inappropriate response 
or integration of these signals lies at the root of many diseases such as cancer. Accordingly it is increas-
ingly recognised that changes in the extracellular environment can drive tumorigenesis, tumor progres-
sion and metastasis, and can act dominantly for example over genetic aberrations in the tumor cells. Focus-
ing on the extracellular matrix and the immune system, in this talk I will discuss some of our recent fi nd-
ings about how the microenvironment regulates tumor metastasis.
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L6: NOVEL MECHANISMS OF TUMOR-STROMA CROSSTALK
ESTHER ARWERT1, EMMA MILFORD1, ANTONIO RULLAN1, ALAN MELCHER2, 
KEVIN HARRINGTON2, ERIK SAHAI1
1 Sahai Lab, Francis Crick Institute, London, United Kingdom 
(e-mail: Erik.Sahai@crick.ac.uk) 
2 Institute of Cancer Research, London, United Kingdom
We will present data on the mechanism of cooperation between cancer cells and stromal fi broblasts. 
Many tumors show an initial response to targeted therapies before genetic resistance emerges, however 
litt le is known about how tumor cells tolerate therapy before genetic resistance dominates. We show how 
the ECM generates a ‘safe haven’ in which melanoma cells can tolerate targeted therapy. This supports the 
population of cancer cells from which genetically resistance emerges. These data argue fi broblast – cancer 
cell cross-talk via the ECM. We have recently uncovered a novel mechanism of tumour – stroma cross-talk 
involving a pathological heterotypic cell-cell contact. In normal skin, epithelial cells and fi broblasts do not 
contact because they are separated by a basement membrane. However, a signature feature of tissue dam-
age and invasive squamous cell carcinoma is breakdown of the basement membrane, epithelial cells and 
fi broblasts can then contact each other. This heterotypic can transmit force and enable invasion. More 
crucially, it triggers dramatic changes in chemokine, cytokine, and other infl ammatory modulators trig-
gering anti-microbial and anti-viral responses. We propose that this represents a tissue level damage sens-
ing mechanism analogous to molecular DAMPs.
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L7: HEDGEHOG/GLI SIGNALING: TARGETS AND TARGETING
PETER G. ZAPHIROPOULOS, YUMEI DIAO, ANI AZATYAN
Department of Biosciences and Nutrition, Karolinska Institutet, Stockholm, Sweden 
(e-mail: Peter.Zaphiropoulos@ki.se)
Although the Glioma associated oncogene 1 (GLI1) acts as the ultimate eff ector of Hedgehog signal-
ing litt le is known on the target genes of this transcription factor. Via RNA sequencing and correlation 
analysis with FANTOM5, a signature of 29 GLI1 target genes has been identifi ed. One of the prominent 
novel targets, FOXS1, a transcription factor previously implicated in nervous system development, is 
highly expressed in the Sonic Hedgehog class of medulloblastoma tumors. Importantly, FOXS1 blocks the 
capacity of GLI1 to activate target genes and elicits opposite eff ects on tumor cell proliferation compared 
to GLI1. These fi ndings suggest that FOXS1 may have tumor suppressive properties and could be a marker 
of good prognosis [1].
Eff orts to target Hedgehog signaling-dependent cancers have focused on the small molecule RITA, 
which is considered to be an activator of the p53 tumor suppressor. RITA treatment of cancer cells down-
regulated Hedgehog signaling, however this was independent of p53 and mediated via the MAP kinase 
JNK. Treatment of rhabdomyosarcoma xenografts with RITA suppressed tumor growth, as did GANT61 
a small molecule that is thought to inhibit the GLI factors. RT/PCR analysis of GLI1, GLI2 and PTCH1 
expression in the tumor xenografts revealed more pronounced downregulation by RITA than by GANT61. 
Surprisingly, the combinatorial RITA and GANT61 treatment did not further suppress tumor growth sug-
gesting a certain antagonism of the two drugs [2].
REFERENCES:
1.  Diao Y, Rahman MF-U, Vyatkin Y, Azatyan A, St Laurent G, Kapranov P, Zaphiropoulos PG. Identifi cation of GLI1 
target genes and regulatory circuits in human cancer cells. Mol Oncol. 2018;12(10):1718-1734.
2.  Azatyan A, Gallo G, Diao Y, Selivanova G, Johnsen JI, Zaphiropoulos PG. RITA downregulates Hedgehog-GLI in 
 medulloblastoma and rhabdomyosarcoma cells via JNK-dependent but p53-independent mechanism. Cancer Lett ers. 
2018. [under editorial-requested revision]
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L8: TARGETING ONCOGENIC HEDGEHOG SIGNALING BEYOND 
SMOOTHENED INHIBITORS
ELISABETH PEER1, WOLFGANG GRUBER1, FILIP VILOTIC1, THOMAS PARIGGER2, 
SVETLANA HAMM3, RENE BARTZ3, FRITZ ABERGER1
1 Department of Biosciences, Cancer Cluster Salzburg, Paris-Lodron University of Salzburg, Salzburg, Austria 
(e-mail: fritz .aberger@sbg.ac.at) 
2 Salzburg Cancer Research Institute, Cancer Cluster Salzburg, University Clinic Salzburg, Salzburg, Austria 
3 4SC AG, Planegg-Martinsried, Munich, Germany
Aberrantly activated Hedgehog/GLI (HH/GLI) signaling has been identifi ed as driver signal in a 
number of cancer entities with a critical role in the maintenance of rare and highly malignant cancer stem 
cells (CSC). Eradicating tumor-initiating metastatic CSCs by targeted inhibition of CSC pathways such as 
HH/GLI is of high medical need. Clinically advanced inhibitors of the essential HH pathway eff ector 
Smoothened (SMO) showed promising effi  cacy as a fi rst-line therapy in skin cancer, though the rapid 
development of drug resistance paired with frequent SMO-independent activation of GLI factors limit 
their applicability. The identifi cation and targeting of further GLI-regulating eff ectors downstream of 
SMO is, therefore, an important step towards overcoming SMO-inhibitor (SMOi) resistance and improved 
disease management.
We will discuss novel druggable targets within the HH/GLI pathway and demonstrate that selective 
inhibition of these pathway eff ectors holds promise for future therapeutic applications, particularly for 
rational combination treatments.
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L9: NON-CANONICAL HEDGEHOG SIGNALLING: 
IS IT IMPLICATED IN CANCER?
NATALIA RIOBO-DEL GALDO
School of Cellular and Molecular Biology and Leeds Institute of Medical Research, University of Leeds, Leeds, 
United Kingdom 
(e-mail: N.A.Riobo-DelGaldo@leeds.ac.uk)
Non-canonical Hedgehog (HH) signalling refers to a plethora of cellular responses to HH proteins 
that are not mediated by stimulation of the GLI family of transcription factors. We have described two 
types of non-canonical signalling: a Type I Patched1 (PTCH1)-dependent and a Type II that is mediated by 
Smoothened (SMO). Here I will discuss the recent fi ndings in novel non-canonical HH pathways and evi-
dence of their relevance in cancer, in particular of epithelial cancers with upregulation of HH proteins and 
with mutations in the C-terminal domain of PTCH1.
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L10: THE GLI CODE IN OVARIAN CANCER
MAJA SABOL, NIKOLINA RINČIĆ, DIANA TRNSKI, VESNA MUSANI, PETAR OZRETIĆ, 
SONJA LEVANAT
Laboratory for Hereditary Cancer, Division of Molecular Medicine, Ruđer Bošković Institute, Zagreb, Croatia 
(e-mail: maja.sabol@irb.hr)
Ovarian tumors are a heterogenic malignancy, often named “the silent killer” due to lack of symp-
toms, which leads to late detection of the disease. It is often diagnosed in the advanced stages when the 
tumor has already spread. Additional complication are the diff erent tissues of origin for diff erent tumor 
types, or even of the same subtype. The Hedgehog signaling pathway has been implicated in ovarian 
tumors by several diff erent mechanisms. Hyperactivation of the Hedgehog pathway can occur via hyper-
methylation of PTCH1 promoter, mutations in PTCH1 gene, microRNA activity, or through cross-talk 
with other signaling pathways. All these events eventually lead to activation of GLI proteins and to tilting 
the balance imparted by the GLI code towards activation of the pathway. Expression of GLI1 is usually 
associated with tumor progression in a clinical sett ing, but GLI2 and GLI3 also play a role by modifying 
the activity of GLI1 and transcription of their common transcriptional targets. In ovarian cancer, GLI3 
protein is expressed in the full-length activator form, and not the shortened repressor form which is the 
predominant form for GLI3 protein. CRISPR/Cas9-generated knock-out ovarian cancer cell lines for each 
of the three GLI proteins show that all three GLI proteins are relevant for the pathway activation in ovarian 
cancer, including GLI3 which is usually considered a repressor.
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L11: AN INTEGRATED MODEL OF HEDGEHOG-GLI MOLECULAR 
FUNCTIONS IN CANCER
BARBARA STECCA
Tumor Cell Biology Unit - Institute for Cancer Research and Prevention (ISPRO), Florenze, Italy 
(e-mail: b.stecca@ispro.toscana.it)
The Hedgehog-GLI signaling is a key pathway critical in embryonic development, stem cell biology 
and tissue homeostasis. Aberrant activation of Hedgehog-GLI signaling has been linked to several types 
of cancer, including those of the skin, brain, lungs, prostate, gastrointestinal tract and blood. Canonical 
Hedgehog-GLI pathway activation is triggered by binding of Hedgehog ligands to the transmembrane 
receptor PATCHED and is mediated by transcriptional eff ectors that belong to the GLI family, whose 
activity is fi nely tuned by a number of molecular interactions and post-translation modifi cations. The 
activity of the GLI proteins can be also regulated by numerous proliferative and oncogenic inputs, in addi-
tion or independent of upstream HH signaling. In turn, the GLI transcription factors exert their activities 
in cancer cells through a number of specifi c targets, including regulators of proliferation and diff erentia-
tion, survival, angiogenesis, self-renewal, epithelial-mesenchymal transition and invasiveness.
We and others have described a number of targets of the GLI, such as E2F1 and SOX2, but the mecha-
nisms of action seem to be critical to understand how the GLI transcription factors integrate diff erent 
oncogenic molecular functions and how this information nexus operates. Here we will show how the 
Hedgehog/GLI-E2F1 axis regulates iASPP, providing an additional mechanism by which Hedgehog sig-
naling restrains p53 pro-apoptotic function in melanoma cells. In addition, we will present recent fi ndings 
on the positive autoregulatory loop between GLI1 and SOX2 in cancer stem cells and on the identifi cation 
of novel common targets of GLI1 and SOX2. Finally, we will discuss the implications of the integrated 
model of Hedgehog-GLI molecular functions for anti-cancer therapy.
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L12: IMMUNOTHERAPY OF HEMATOLOGICAL MALIGNANCIES: 
A SUCCESS STORY
IGOR AURER
University Hospital Centre Zagreb and Medical School, University of Zagreb, Zagreb, Croatia 
(e-mail: igor.aurer@mef.hr)
In the last decades immunotherapy of hematological neoplasms became a very important and eff ec-
tive therapeutic approach, substantially increasing response rates, progression-free and overall survival of 
patients. Non-conjugated monoclonal antibodies (MoAbs), mostly directed against the CD20 antigen, the 
prime example being rituximab, are used as monotherapy, or more frequently in combination with che-
motherapy, in the treatment of mature B-lymphoid neoplasms. Despite decades of use, the mode of action 
of rituximab is still not completely clear. Proposed mechanisms include complement-dependent cytotoxic-
ity (CDC), antibody-dependent cellular cytotoxicity (ADCC), induction of apoptosis and increased sensi-
tivity to cytotoxic agents. Rituximab has very litt le toxicity (except for depletion of normal B-cells which is 
surprisingly well tolerated) or off -target eff ects. Obinutuzumab, an anti-CD20 MoAb with more pro-
nounced ADCC and less CDC than rituximab, is more eff ective than the latt er in only a limited number of 
lymphoma types but causes more frequently neutropenia, making it more diffi  cult to combine with che-
motherapy.
Brentuximab vedotin is an example of an eff ective MoAb conjugated to a cytotoxic agent. It is directed 
against CD30, an antigen present on Hodgkin and some non-Hodgkin lymphomas. In contrast to CD20, 
which remains on the cell surface amenable to host eff ector mechanisms, CD30 is internalized after MoAb 
binding and cell killing results from the intracellular action of the cytotoxic agent.
Transplantation of allogeneic hematopoietic stem cells (AlloSCT) is an example of cellular immuno-
therapy of hematologic neoplasia. A signifi cant part of the effi  cacy of this very eff ective and very toxic 
therapeutic option is due to the graft-versus tumor eff ect mediated by alloreactive immunocompetent 
donor cells. Advances in AlloSCT include the use of reduced-intensity conditioning and haploidentical 
related donors, enabling its use in older patients and those with few or no siblings. Immunomodulatory 
agents, thalidomide, lenalidomide and pomalidomide are a mainstay of multiple myeloma therapy. While 
their modes of action are multifaceted, stimulating host immune responses seems to be a very important 
part of it.
Finally, new treatment approaches with exciting preliminary results include the use of bispecifi c anti-
bodies and chimeric antigen receptor T-cells (CAR-T).
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L13: TARGETING MEDULLOBLASTOMA METASTATIC TUMORS VIA 
IMMUNOMODULATION THERAPY
VERONICA FERRUCCI1,2,3, FATEMEH ASADZADEH2, ROBERTO SICILIANO2, LUISA DASSI2, 
ANTONELLA VIRGILIO4, ALDO GALEONE4, LUCIA DE MARTINO6, LUCIA QUAGLIETTA6, 
MARIA ELENA ERRICO5, VITTORIA DONOFRIO5, MARC REMKE7, DANIEL PICARD7, 
LOUIS CHESLER8, FREDRIK J. SWARTLING9, WA. WEISS10, PASQUALINO DE ANTONELLIS11, 
MICHAEL D. TAYLOR11,12, GIUSEPPE CINALLI6, MASSIMO ZOLLO1,2,3
1 Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università degli Studi di Napoli Federico II, 
Naples, Italy 
2 CEINGE Biotecnologie Avanzate, Naples, Italy 
3 European School of Molecular Medicine (SEMM), Milan, Italy 
(e-mail: massimo.zollo@unina.it) 
4 Dipartimento di Farmacia, Università degli Studi di Napoli Federico II, Naples, Italy 
5 Surgical Pathology, Ospedale Santobono-Pausilipon, Naples, Italy 
6 Paediatric Neurosurgery, Ospedale Santobono-Pausilipon, Naples, Italy 
7 German Cancer Consortium (DKTK), Department of Paediatric Oncology, Haematology, 
and Clinical Immunology, University Hospital Düsseldorf, Düsseldorf, Germany 
8 Division of Clinical Studies, The Institute of Cancer Research, London SM2 5NG, United Kingdom 
9 Science for Life Laboratory, Rudbeck Laboratory, Department of Immunology, Genetics and Pathology, 
Uppsala University, Uppsala, Sweden 
10 Department of Neurology, University of California, San Francisco, San Francisco, CA, USA 
11 Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto ON, Canada 
12 Arthur and Sonia Labatt  Brain Tumour Research Centre, The Hospital for Sick Children, Ontario, Canada
Medulloblastoma (MB), an embryonal tumour of the cerebellum, accounts for 25% of childhood 
 central nervous system (CNS) tumors. The molecular classifi cation of MB identifi ed 4 molecular entities 
(WNT, SHH, Group 3, Group 4) that were further classifi ed into 12 subtypes with distinct transcriptional 
profi les, somatic mutations and clinical outcomes. MB Group 3 has the worse prognosis due to the higher 
tendency to metastatize in the leptomeningeal space (40% of children at diagnosis). The clinical manage-
ment includes surgical resection followed by chemo-radiation regimens. The lack of a targeted-therapy for 
metastatic MB is also due to the absence of genetically engineered mouse models (GEMMs) resembling 
metastatic MB Group 3.
The brain tumour microenvironment (TME; tumour associated macrophages, microglia, dendritic 
cells, T-cells) are emerging as critical regulators of cancer progression also in MB. Immunotherapeutic 
strategies, based on immunomodulatory drugs pomalidomide or dendritic cells vaccines, are in Phase 1/2 
clinical trials.
We identifi ed a new “metastatic axis” in MB Group 3 driven by PRUNE-1. We found the overexpres-
sion of Prune-1 enhances TGF-beta pathway thought is binding to NME-1, thus leading to OTX2 up-regu-
lation, EMT, and PTEN inhibition. We identifi ed a non-toxic small molecule (pyrimido-pyrimidine deriva-
tive, AA7.1) with the ability to impair MB Group 3 metastatic dissemination in vivo by targeting Prune-1. 
Of importance, through WES applied to primary human metastatic MB cells, we identifi ed ‘non-synony-
mous homozygous’ deleterious variants aff ecting immune cells activation/diff erentiation, taking part to a 
protein network of relevance for metastatic processes, thus highlighting a role for immune cells in meta-
static MB. Recently, we developed a GEMM of PRUNE-1-driven-metastatic MB Group 3. Anatomo-path-
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ological analyses performed in our model and in a cohort of MB Group 3 patients show the presence of 
FOXP3 infi ltrating cells in the brain TME, thus suggesting a role for Regulatory T-cells in MB Group 3.
Our in vitro data measuring the proliferation of MB Group 3 cells show the anti-Prune-1 drug to act 
synergistically with chemotherapeutics currently used in clinics for MB. The anti-Prune-1 drug also exerts 
immunomodulation in vitro and in vivo by reducing infl ammatory cytokines and the immune cells in 
TME. To our knowledge, this is one of the fi rst immunotherapeutic approach in a preclinical model of 
metastatic MB Group 3.
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Integrins are heterodimeric glycoproteins that bind cells to extracellular matrix proteins. The connec-
tion between integrins and the cytoskeleton is mediated by a dynamic integrin adhesion complex (IAC), 
which transduces chemical and mechanical signals to control a multitude of cellular functions, including 
sensitivity to antitumor drugs, migration and invasion. Methods based on proteomics enable the analysis 
of IAC, the composition of which has been termed adhesome. Our recent focus has been the characterisa-
tion of integrin αV-dependent adhesome in three tumor cell models. The fi rst one is tongue squamous 
carcinoma Cal27 cell model composed of Cal27 cells and a cell clone obtained by stable transfection of 
integrin subunit β3 cDNA that led to de novo expression of integrin αVβ3 conferring decreased sensitivity 
to cisplatin, mitomycin C, doxorubicin and 5-fl uorouracil, and increased cell migration and invasion. The 
other two cell models were selected based on our recently published data showing that knockdown of 
integrin αV sensitizes melanoma cell line MDA-MB-435S and triple negative breast carcinoma cell line 
MDA-MB-231 to vincristine and paclitaxel. Therefore, the second model involves cell line MDA-MB-435S 
and corresponding cell clone isolated by stable transfection of integrin αV-specifi c shRNA expressing 
plasmid demonstrating increased sensitivity to vincristine and paclitaxel, and decreased migration, which 
is consistent with transient transfection data. Interestingly, sensitivity patt ern of the MDA-MB-231 cell 
model was not in line with transient transfection data whereas MDA-MB-231 cell clone with decreased 
amount of integrin αV demonstrated decreased sensitivity to paclitaxel and vincristine, but still, decreased 
migration. To precisely understand the role of integrins αV, preferentially αVβ3 and αVβ5, in regulating 
IAC in tumor cells, we characterised by mass spectrometry (MS), the adhesome of Cal27, MDA-MB-435S 
and MDA-MB-231 cell lines grown in standard cell culture conditions and compared it to corresponding 
stable cell clones expressing altered amount of integrin αV. MS data enables the assessment of main inte-
grins used by tumor cells and the analysis of the composition of IAC recruited by integrins αV. These data 
represent a valuable resource for improving our understanding of the composition of IAC and of the 
mechanisms involved adhesion control of cell sensitivity to antitumor drugs, migration and invasion.
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L15: TARGETED THERAPIES FOR HER2 POSITIVE METASTATIC BREAST 
CANCER PATIENTS
PAULA PODOLSKI, NERA ŠARIĆ
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(e-mail: podolski.paula@gmail.com)
The amplifi cation of the human epidermal growth factor receptor 2 (HER2) is observed in 20-25% of 
all breast cancers. Targeting HER2 receptor has led to improved outcomes for patients with metastatic 
breast cancer, and is considered as major progress in breast cancer therapy. The HER2-targeted agents 
currently approved for treatment of metastatic breast cancer are trastuzumab, pertuzumab, trastuzumab-
emtansine and lapatinib. They are used in diff erent combinations with each other and with other chemo-
therapeutic agents. Patients with hormone receptor-positive (ER and/or PgR) and HER2-positive disease, 
should receive HER2-directed therapy as a component of their fi rst-line treatment, while endocrine ther-
apy is administrated following induction chemotherapy plus HER2-directed therapy. Although these 
drugs improve progression-free survival and overall survival, they are generally not curative in the meta-
static sett ing in the majority of patients, due to several mechanisms of anti-HER2 therapy resistance. There 
are a few prognostic biomarkers, but still no predictive biomarkers to guide the treatment selection of 
metastatic HER2 targeted therapy. Important is to continue research into the biology of HER2-positive 
breast cancer, including investigation of resistance pathways and their interaction with our immune sys-
tem. The wide range of the next generation of therapies are under development. They include: new tyro-
sine kinase inhibitors (TKI) targeting HER2 receptors and inhibitors of their down-stream signaling (nera-
tinib, afatinib, tucatinib); inhibitors of the cell cycle (CDK4/6 inhibitors), HSP90 and angiogenesis; HER2 
targeted antibody-drug conjugates (ADC) and immunotherapy aimed at HER2-positive breast cancer 
(magretuximab, ertumaxomab, checkpoints inhibitors).
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Tumor mutation status has become an important part of molecular diagnostics that enables optimal 
treatment response. Genetic screens for somatic mutations are performed on genes including KRAS, BRAF 
and NRAS that are known to be frequently mutated in CRC tumors and confer resistance to therapies 
directed against EGFR signaling pathway. Considering that these mutations provide a selective advantage 
for tumor cell survival, detecting somatic mutations present in wild type background with as low as < 0.1% 
is of potential diagnostic utility. Currently, the main source of tumor DNA for mutation detection is FFPE. 
However, in recent years liquid biopsy has become a promising alternative. While the use of liquid biopsy 
is not included in current protocols for mCRC patient management, it has been extensively studied as a 
non-invasive method for both treatment response and patient monitoring.
The aim of the study was to determine the cfDNA levels and the KRAS and BRAF mutation status in 
patients who underwent surgical removal of primary CRC. Since cfDNA in the bloodstream can be of 
various origins (diff erent necrotic / apoptotic processes), we compared cfDNA concentrations of CRC 
patients to two additional groups (hemorrhoid patients and healthy individuals). cfDNA was isolated 
from serum and its concentration measured with our custom designed human gDNA ddPCR assay which 
enables effi  cient and specifi c measurement of low concentrations of human DNA. The highest concentra-
tion of cfDNA was measured in CRC patients group (average 0.44 ng/ul), while both hemorrhoid patients 
and healthy individuals had signifi cantly lower average concentrations, 0.25 ng/ul (* p = 0.01) and 0.08 ng/
ul (p = 0.0001), respectively. Elevated cfDNA concentration must be interpreted with caution since other 
factors in addition to cancer can be the cause of higher cfDNA serum concentrations. All patients were 
previously screened for somatic mutations in the 12 and 13 KRAS codons and the BRAF V600E mutation 
using the SNaPshot Multiplex System. Mutations were confi rmed with Sanger sequencing. Mutations 
were detected in some of the primary tumors, but their presence in the serum was not confi rmed with the 
use of the above mentioned method. In the current study, we detected the same mutations using BioRad’s 
ddPCR mutation assays and showed that ddPCR is the method of choice when more sensitive measure-
ments are required in molecular diagnostics in oncology.
Labena d.o.o. Sponsored Lecture
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Sirtuin 3 (Sirt3), a major mitochondrial NAD+-dependent deacetylase, has bifunctional role in cancer 
tumorigenesis, acting as both oncogene and tumor suppressor, depending on the tissue and cancer-type 
specifi c metabolic programs. Changes in its expression are associated with the excessive production of 
reactive oxygen species (ROS), thus contributing to mitochondrial dysfunction and age-related patholo-
gies. Hyperoxic treatment (i.e. generator of ROS) was shown to support some tumorigenic properties, but 
fi nally suppresses growth of certain mammary carcinoma cells. 70% of all breast cancer cases are estrogen 
receptor (ER) positive and express ER-alpha (ER-α). While ER-α positive cancers are more receptive to 
hormonal therapy, triple negative breast cancers (TNBC) are characterized by an aggressive behaviour 
and the lack of targeted therapeutic strategies. Due to strikingly reduced Sirt3 level in many breast cancer 
cells, we aimed at deciphering the eff ect of de novo Sirt3 expression in normoxic and hyperoxic conditions 
in the human breast cancer cells. Although we have recently shown that Sirt3 acts as a tumor suppressor 
in non-invasive (ER-α positive) breast cancer cells, it remains unclear whether this eff ect is mediated 
through ER-α signalling pathway. Therefore, we stably transfected both MCF-7 (ER-α positive) and MDA-
MB-231 (TNBC) cells with Flag-tagged Sirt-3 plasmid and characterized Sirt-3 overexpressing clones in 
normoxic and hyperoxic conditions. To further characterize clones and decipher the cause of the observed 
diff erences in their response, we used combination of treatments to alter the expression and activity of 
diff erent proteins. We monitored the expression of proteins involved in mitochondrial biogenesis, glycoly-
sis, metabolic regulation and antioxidant defense. Furthermore, we compared the growth rate, metabolic 
activity, mitochondrial ROS production and the cell cycle of the clones. Initial fi ndings showed enhanced 
susceptibility of MCF-7 cells to hyperoxia and decreased cellular growth upon de novo Sirt3 expression. 
On the other hand, Sirt-3 markedly promoted growth of highly invasive MDA-MB-231 cells. Collectively, 
results suggested that Sirt-3 may either have a tumor suppressing or tumor promoting role in breast can-
cer cells depending on their invasiveness, thus giving us a rationale for further studies on Sirt3 and hyper-
oxia as an adjuvant tumor therapy in breast cancer malignancies.
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Idiopathic pulmonary fi brosis (IPF) is an irreversible disease, with a rising incidence in the world. 
Characteristics of the disease are distorted lung architecture and progressive loss of functional tissue. 
Although the complete pathogenesis of the disease is still unclear, the hypothesis of alveolar epithelium 
micro-injuries and abnormal tissue repair has been frequently reported. Due to the limits of approved 
therapies in IPF, emerging need for the new therapeutic targets and the eff ective compounds is present. 
Wingless/integrase-1 (Wnt) signalling pathway recently gained emerged att ention in the pathogenesis and 
progression of IPF. Many studies have reported the implication of dysregulated Wnt signalling in lung 
remodelling, pulmonary myofi broblast proliferation and epithelial to mesenchymal transition. In line 
with this, an increased expression of the Wnt signalling pathway related genes was observed in the lung 
tissue of diagnosed individuals. Wnts, in particular, Wnt 3α protein play a key role in matrix remodelling, 
tissue repair and fi brogenesis. The aim of the present study was to detect the localisation of the Wnt-3α 
protein in the lung tissue of the murine bleomycin-induced lung fi brosis.
In short, C57Bl/6 mice were administered intranasally with bleomycin (BLM) or saline (vehicle). Ani-
mals were sacrifi ced on day 21 post-challenge and the lungs were paraffi  n embedded. The expression of 
Wnt-3α was evaluated by immunohistochemistry on lung tissue slides. Quantifi cation of Wnt-3α expres-
sion was analysed in digital pathology imaging software (Calopix, TRIBVN) on scanned slides (AxioScan.
Z1, Zeiss) using immuno-object protocol. At day 21 post IN administration, the percentage of the Wnt-3α 
positive objects on slides was statistically increased in animals challenged with BLM. In naïve murine 
lungs, Wnt-3α was strongly expressed by bronchial epithelial cells. In BLM challenged animals, strong 
Wnt-3α expression was observed within the cytoplasm of a subset of bronchial epithelial cells. Honey-
comb epithelial cells were Wnt-3α positive, as well as a proportion of cells in the fi bro-infl ammatory area.
In summary, our study shows a strong expression of the Wnt-3α protein in the lungs of BLM-chal-
lenged mice. It implicates that our 21-day model of BLM induced lung fi brosis is a good basis for the fur-
ther evaluation and can be a suitable platform for the investigation of the potent Wnt/β-catenin target 
molecules.
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Head and Neck Squamous Cell Carcinoma (HNSCC) is the 7th most frequent malignancy in the 
world, with a very low 5-year survival. It is known that the main risk factors associated with this carci-
noma are excessive tobacco and alcohol consumption together with high-risk types of human papilloma-
virus (HPV). Still, there is a strong need to fi nd new, good biomarkers of this disease. The most appropri-
ate biomarkers would be those that would point out changes in epithelial cells before carcinoma occur-
rence. DNA methylation is irreversible change that inhibits gene expression. Altered DNA methylation is 
one of the possible factors associated with the HNSCC development. The presumption is that epigenetic 
biomarkers, such as methylated genes could point to changes even before they can be clinically detected. 
The model on which we explore those changes of DNA methylation are normal oral mucosa tissue, poten-
tially malignant lesions of the oral mucosa, oral lichen planus (OLP) and oral lichenoid lesions (OLL) and 
HNSCC tissue. OLP and OLL are diffi  cult to distinguish clinically and histopathologically, so early detec-
tion and distinguishing by epigenetic tools would be of great importance in further treatment. Herein, we 
will discuss DNA methylation profi ling of diff erent diagnosis by Infi nium MethylationEPIC BeadChip 
array and pyrosequencing methods. The main goal was to reveal DNA methylation diff erences in normal 
oral samples, possible in oral lesions, and in HNSCC samples. The results obtained with Infi nium Methyl-
ationEPIC BeadChip array showed a panel of gene promoters signifi cantly methylated in HNSCC samples 
in comparison to normal samples, mainly of genes related with receptor and transmembrane functions 
and transcription activity. Some of them are included in cell cycle, cellular growth, transformation, apop-
tosis and autophagy. The group of hypomethylated gene promoters in HNSCC, in comparison to normal 
oral mucosa, and lesions, was mainly involved in immune response and transcriptional regulation.
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Breast cancer is the second cause of mortality among women. Due to insuffi  ciency of existing thera-
pies, novel therapeutic agents need to be developed in cancer treatment. Cucurbitacin B (CuB) is a triter-
penoid compound isolated from Cucurbitaceae plants. The anticancer potential of this compound has 
shown in various cancer cells. Because of poor solubility of CuB, the extensive use of this potent anticancer 
compound is prohibited. Among various approaches nanocarriers such as lipid polymer hybrid nanopar-
ticles appear to be a more promising strategy for the delivery of CuB. This study is designed to optimize 
and investigate the eff ect of various hybrid nanocarriers of CuB by using a DoE approach. The eff ects of 
these nanocarriers on alteration of mitochondrial potential have been investigated in estrogen +/- breast 
cancer cells. The hybrid nanocarriers were produced by one step self-assembly approach and the optimi-
zation studies were performed by a two-factor, three-level full factorial design with a center point (32). The 
eff ects of nanocarriers on cell proliferation were determined by MTT assay and cell cycle analysis was 
performed subsequently in MCF-7 and MDA-MB-231 breast cancer cell lines. The apoptosis was evaluated 
by annexin-V binding assay with fl ow cytometry and fl uorescence imaging studies. The alteration on 
mitochondrial membrane potential has been determined by mitopotential assay that detects the amount 
of live and depolarized cells. In this research, CuB-encapsulated lipid-polymer hybrid nanocarriers were 
successfully produced. The encapsulation effi  ciency of nanocarriers ranged from 49.35% to 80.00%. The 
nanocarriers signifi cantly inhibited cell proliferation at 0.1 μM and higher concentrations in both cell lines 
(p<0.01). The results showed that MCF-7 cells were more prone to apoptotic induction in that the apoptotic 
cell population % was signifi cantly elevated (p<0.05). The results also indicated that the nanocarriers 
induced a signifi cant decrease in mitochondrial membrane potential in both cell lines. In conclusion, this 
work has demonstrated that CuB loaded lipid polymer hybrid nanocarriers signifi cantly induced apopto-
sis in both estrogen +/- breast cancer cells through triggering the downstream events in the apoptotic cas-
cade and should be considered as potential candidate drug carriers for further investigations.
This work was supported by The Scientifi c and Technological Research Council of Turkey with 
117S131 project number.
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DNA-protein crosslinks (DPC) are type of DNA lesions where a protein becomes irreversibly cova-
lently bound to DNA upon exposure to endogenous or exogenous crosslink inducers. DPCs present a 
physical blockage to all DNA transactions: replication, transcription, recombination and repair and there-
fore the consequences of impaired DNA-Protein Crosslink Repair (DPCR) are severe. Considering their 
frequent occurrence and detrimental eff ect on all DNA transactions, it is not surprising that DPCs are 
implicated in aging, cardiovascular diseases, neurodegeneration and cancer. On a cellular level, aberrant 
DPC repair leads to the formation of DSBs, genomic instability and/or cell death, while on the organismal 
level impaired DPCR was so far shown to cause premature aging phenotypes and cancer. The discovery 
of proteolysis-coupled DPC repair centred on SPRTN and Wss1 proteases led to recognition of DNA-
protein crosslink repair as a separate DNA damage repair pathway. However, we currently do not know 
how is the pathway orchestrated and which factors besides proteases are involved, while almost nothing 
is known of DPCR mechanism in vivo. Therefore, within this project we aim to unravel the orchestration 
of the DPCR pathway in vivo using zebrafi sh (Danio rerio) as a well-characterized vertebrate model. 
Zebrafi sh has been increasingly recognized as a valuable cancer model in studying melanoma and meta-
static behaviour of various human cancers including glioblastoma and aggresive forms of breat cancer. We 
use CRISPR/Cas9 gene manipulations to knock-out or mutate specifi c gene of interest in zebrafi sh fol-
lowed by analysis of DPC levels and wide range of phenotypes in zebrafi sh embryos and adults. We aim 
to show unequivocal link between DPCR and cancer emergence on the organismal level, with the aim of 
developing more effi  cient cancer therapies target.
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Metastasis formation represents one of the well-known hallmarks of cancer and is one of the leading 
causes of cancer-related deaths. It starts with the dissemination of cancer cells from the primary tumor site 
and a local invasion of the surrounding tissue. This is followed by intravasation of the tumor cells, their 
survival in the circulatory system, extravasation and eventually re-colonization at a distant organ, thus 
generating a secondary tumor. All of these individual steps require specifi c features of tumor cells, which 
are largely connected to the epithelial-to-mesenchymal transition and cancer stem cell (CSC) phenotypes. 
Mostly due to their ease of use and low costs, two-dimensional cell culture systems are commonly applied 
in cancer research. However, these systems can only partially capture processes or characteristics associ-
ated with the formation of metastases in patients. For this reason, various three-dimensional experimental 
model systems have been established that are able to bett er mimic the in vivo situation. In our studies, we 
are applying several of these 3D cell culture and spheroid-based models in order to investigate the inva-
siveness of tumor cells, e.g. dependent on gene-specifi c knockouts or their CSC potential. Additionally, we 
are utilizing the in vivo chorioallantoic membrane assay as an alternative to animal experiments. Within 
this model system, we are not only able to elucidate the role of new potential metastatic players or CSC 
sub-populations during the individual steps of the metastatic cascade in more detail, but we can also 
investigate further hallmarks of cancer that contribute to tumor aggressiveness such as cell proliferation 
and tumor angiogenesis.
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Berberine is an isoquinoline alkaloid extensively used for centuries in the traditional medicine. Recent 
studies showed that berberine possesses good anticancer therapeutic potential. The objectives of our study 
were to elucidate eff ect of berberine against 3D cell culture model, and to compare berberine activity 
against 2D and 3D models. IC50 value of berberine in 2D model was obtained using MTT test during 72h 
incubation, against human cervix adenocarcinoma cells (HeLa). The concentrations (IC50, 3IC50, 5IC50, 
10IC50) were tested on 3D spheroids of HeLa cells formed by Hanging drop method during 72h. Morpho-
logical changes in cells after 72h, in both models, were analyzed by fl uorescence microscope. The treated 
cells were stained with a mixture of acridine orange and ethidium bromide dyes. The positive control was 
cisplatin. IC50 values for berberine and cisplatin were 2.5 and 1.2 μg/mL. The concentrations of berberine 
(2.5, 7.5, 12.5, and 25 μg/mL) and cisplatin (1.2, 3.6, 6, 12 μg/mL) were added to cell spheroids. After 24h 
we observed spheroid contraction and diameter reduction in all samples treated with berberine or cispla-
tin. After 72h the trend of spheroid reduction was continued in cells treated with cisplatin or berberine in 
lower concentrations (IC50 and 3IC50). Samples treated with higher concentrations of berberine (5IC50 
and 10IC50) showed loss of density and compactness, and consequently increase in the diameter. In con-
trol sample diameter increased during 24 and 72h. These results showed diff erent infl uences of berberine 
and cisplatin on extracellular matrix and cell tight junctions in 3D model, which is important for further 
investigation of berberine impact on cancer migration and invasiveness. As expected, morphological char-
acteristics typical for cells in apoptosis were detected in treated 2D models with IC50 concentration of 
berberine or cisplatin. With 3IC50 concentrations all cells were dead. In treated 3D models after 72h ratio 
between corrected total cell green and red fl uorescence showed more viable than dead cells in all samples 
except in samples treated with 10IC50 concentrations of both agents. This result suggested that more com-
plex 3D models require higher concentrations of active principles than 2D models. Our study showed that 
berberine has antitumor potential, which should be subject of further research, and that combination of 2D 
and 3D models gives bett er information of anticancer mechanism of this agent.
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Neutrophil elastase (NE) is a neutrophil-derived serine protease with broad substrate specifi city. We 
have previously shown that NE promotes lung tumor growth in vitro and in vivo and that NE is capable 
of entering tumor cell endosomes in a clathrin-dependent fashion.
Epithelial-mesenchymal transition (EMT) is a fundamental event for primary tumors to metastasize 
to distant sites. Altered gene and protein expression causes changes in cell morphology and behavior, 
resulting in the loss of att achment to neighboring cells, intravasation, and migration into distant tissue. 
However, the entities residing within the tumor microenvironment that drive EMT are poorly understood.
We identifi ed NE, expressed and released by tumor-associated neutrophils, as such an entity. We 
found that NE induces EMT-like morphology and behavior in several cancer cell lines as well as upregu-
lates proteins (N-cadherin, α-SMA, Fibronectin and Vimentin) associated with EMT. Furthermore, NE 
provokes tumor cell migration and invasion in vitro and is required for metastasis formation in vivo. 
Besides known EMT markers we identifi ed signifi cant upregulation of inhibitor of DNA binding 1 (ID1) 
in tumor cells in the presence of NE. Increased ID1 expression was previously shown to correlate with 
tumor progression and metastasis. Clathrin-dependent NE internalization is required for both ID1 expres-
sion and the EMT-like phenotype. We localized NE in diff erent compartments of tumor cells and found it 
predominantly in the nuclear fraction; more specifi cally, NE is located in the chromatin-bound fraction, 
indicating a potential role in chromatin remodeling and transcriptional regulation. Additionally, the pro-
teolytic activity of NE was measured in nuclear and chromatin-bound fractions and is required for induc-
tion of ID1 expression and EMT-like behavior. Taken together, these data suggest the importance of NE-
induced ID1 expression in metastasis formation.
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Development of new cancer therapeutics is expensive and the approval and translation into the clinic 
often take between 10 and 15 years. In contrast, repurposing of drugs already approved for other uses (that 
have been tested in humans, and for which information is available on pharmacology, formulation and 
potential toxicity) enables quick translation into clinical trials and their integration into health care. 
Recently, it has been recognized that therapy for chronic diseases can have an impact on the progression 
and outcome in cancer patients. We examined the eff ects of antihypertensive telmisartan on pancreatic 
ductal adenocarcinoma (PDAC) and metastatic melanoma (MM) cell survival and tumor progression. 
Telmisartan is an angiotensin receptor 1 (AT1R) antagonist and a partial agonist of the peroxisome-prolif-
erator activated receptor γ (PPARγ). In silico analysis showed that both PDAC and MM tumors express 
AT1R and PPARγ receptors, and in vitro both PDAC and MM cell lines were sensitive to telmisartan. In 
PDAC sensitivity to telmisartan inversely correlated with the PPARγ expression level, and telmisartan 
targeted mesenchymal cells more potently. In metastatic melanoma sensitivity correlated with the BRAF 
mutation status and treatment synergized with vemurafenib, BRAF inhibitor used in the clinic. In both 
cancer types telmisartan had extra-receptor eff ects causing metabolic perturbations in glucose consump-
tion, mitochondrial fi ssion and ultimately apoptosis. In vivo, in orthotopically implanted PDAC model, 
telmisartan inhibited the growth of primary tumors, decreased the incidence of liver metastasis and 
improved mouse survival. Taken together, telmisartan showed prominent anti-tumor activity. The eff ec-
tive doses of telmisartan examined in our study can be achieved in patients. Given that telmisartan is 
widely used and safe antihypertensive drug, our fi ndings provide the scientifi c rationale for testing its 
effi  cacy in the chemoprevention of PDAC and melanoma progression.
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Apigenin is a dietary fl avonoid found in several types of vegetables and fruits. Its potential anticancer 
properties were investigated in two types of human breast cancer cells: ER-positive MCF-7 and triple-
negative MDA MB-231 cells. Human peripheral blood lymphocytes were used to elucidate the apigenin’s 
toxicological safety regarding the normal cells. MTT, comet and lipid peroxidation assays were used to 
evaluate cyto- and genotoxicity of apigenin towards cancer cells. Furthermore, the type of apigenin-
induced cell death was analysed using several biomarkers.
Our results revealed that the treatment with apigenin caused changes in cell morphology, in a dose- 
and time-dependent manner. This was followed with apoptosis as a dominant type of cell death in both 
cell lines. Moreover, apigenin exhibited genotoxicity towards cancer cells by inducing oxidative damage. 
Importantly, cell viability and comet assays showed that apigenin was not cytogenotoxic to normal cells.
The observed anticancer activities of apigenin accompanied by its low toxicity towards normal cells 
indicate the possibility of using this dietary fl avonoid as an anticancer agent. Even though the benefi cial 
eff ects of apigenin are promising, further in vitro and in vivo studies are needed to enable its translation 
from bench to bedside.
